Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Notes Payables (2021 - 2023)

Pulse Biosciences has reported Notes Payables over the past 3 years, most recently at $801000.0 for Q1 2023.

  • Quarterly results put Notes Payables at $801000.0 for Q1 2023, changed N/A from a year ago — trailing twelve months through Mar 2023 was $801000.0 (changed N/A YoY), and the annual figure for FY2022 was $917000.0, changed.
  • Notes Payables for Q1 2023 was $801000.0 at Pulse Biosciences, down from $917000.0 in the prior quarter.
  • Over the last five years, Notes Payables for PLSE hit a ceiling of $1.7 million in Q2 2021 and a floor of $98000.0 in Q3 2022.
  • Median Notes Payables over the past 3 years was $859000.0 (2022), compared with a mean of $791666.7.
  • Peak annual rise in Notes Payables hit 90.98% in 2022, while the deepest fall reached 90.98% in 2022.
  • Pulse Biosciences' Notes Payables stood at $1.1 million in 2021, then dropped by 15.56% to $917000.0 in 2022, then dropped by 12.65% to $801000.0 in 2023.
  • The last three reported values for Notes Payables were $801000.0 (Q1 2023), $917000.0 (Q4 2022), and $98000.0 (Q3 2022) per Business Quant data.